Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies ...

The diagnosis? Heart failure with only months to live. However, Eric Borstein fought his way back. With a powerful ...

Eric Borstein, known as “The Walking Guy,” is raising awareness for pulmonary hypertension during PAH Awareness Month through his inspiring story and fundraising.

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved an update to the US product label based on the phase 3 ZENITH trial for ...

Detailed price information for United Therapeutic (UTHR-Q) from The Globe and Mail including charting and trades.

U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study Adding ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S.

Adding WINREVAIR to background PAH therapy improved exercise capacity and WHO functional class (FC), and reduced the risk of clinical worsening events, including hospitalization for PAH, lung ...

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with ...